Back to search
FDAFDA · Food and drugs·Recall number D-0896-2022

Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.

Published June 1, 2022 · Recall initiated: May 13, 2022

Summary

FDA records drug Class III recall D-0896-2022, published June 1, 2022 and initiated May 13, 2022. Recalling firm: GlaxoSmithKline LLC; Status: Terminated; Reported quantity: 328 bottles; Lot: Lot: 2A9E, Exp 1/2027. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

What to do

Voluntary: Firm initiated · Letter

Get an email if TIVICAY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TIVICAY
Manufacturer
GlaxoSmithKline LLC
Distributor
Nationwide in the U.S.
UPC
0349702227132
Lot
Lot: 2A9E, Exp 1/2027
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13. recalled?

Yes. FDA published recall D-0896-2022 on June 1, 2022. Reported hazard: Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TIVICAY. UPC: 0349702227132.